TTY Biopharm Company Limited (TPEX:4105)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
83.20
-1.80 (-2.12%)
At close: Dec 5, 2025

TTY Biopharm Company Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Revenue
6,5035,8945,5065,0624,5364,222
Upgrade
Revenue Growth (YoY)
11.61%7.05%8.77%11.60%7.43%-5.47%
Upgrade
Cost of Revenue
2,8362,4792,2182,0401,7681,617
Upgrade
Gross Profit
3,6673,4153,2873,0212,7682,605
Upgrade
Selling, General & Admin
1,7971,7501,6011,4361,3251,388
Upgrade
Research & Development
181.15271.39310.44353.44287.6261.6
Upgrade
Other Operating Expenses
-8.29-1.444.950.381.43-2.28
Upgrade
Operating Expenses
1,9702,0211,9151,7941,6271,647
Upgrade
Operating Income
1,6971,3941,3721,2281,141957.38
Upgrade
Interest Expense
-38.51-38.26-35.18-22.85-18.97-19.41
Upgrade
Interest & Investment Income
85.6692.2986.6637.5512.6721.4
Upgrade
Earnings From Equity Investments
399.01400.05131.34116.38135.18162.87
Upgrade
Currency Exchange Gain (Loss)
-12.624.970.7723.811.12-15.25
Upgrade
Other Non Operating Income (Expenses)
244.6720.5317.2929.5-178.39101.01
Upgrade
EBT Excluding Unusual Items
2,3751,8931,5731,4121,0921,208
Upgrade
Gain (Loss) on Sale of Investments
0.95--35.74---1.56
Upgrade
Gain (Loss) on Sale of Assets
-1.72-0.95-1.93-3.28-0.74-0.32
Upgrade
Asset Writedown
-26.98-6.8-116.18-0.73-4.15-4.58
Upgrade
Pretax Income
2,3471,8861,4191,4081,0871,202
Upgrade
Income Tax Expense
474.1366.33300.86305.25264.81222.85
Upgrade
Earnings From Continuing Operations
1,8731,5191,1191,103822.57978.68
Upgrade
Minority Interest in Earnings
-82.89-69.739.91-8.79.33-54.5
Upgrade
Net Income
1,7901,4501,1291,094831.89924.18
Upgrade
Net Income to Common
1,7901,4501,1291,094831.89924.18
Upgrade
Net Income Growth
59.87%28.46%3.12%31.55%-9.99%2.68%
Upgrade
Shares Outstanding (Basic)
249249249249249249
Upgrade
Shares Outstanding (Diluted)
249249249249249249
Upgrade
Shares Change (YoY)
0.01%0.04%0.03%-0.02%-0.00%0.03%
Upgrade
EPS (Basic)
7.205.834.544.403.353.72
Upgrade
EPS (Diluted)
7.195.824.534.403.343.71
Upgrade
EPS Growth
60.11%28.48%2.96%31.74%-9.97%2.77%
Upgrade
Free Cash Flow
1,6481,2241,0071,1441,196358.25
Upgrade
Free Cash Flow Per Share
6.624.914.044.594.801.44
Upgrade
Dividend Per Share
4.2004.2003.5003.4003.0004.000
Upgrade
Dividend Growth
20.00%20.00%2.94%13.33%-25.00%-
Upgrade
Gross Margin
56.38%57.94%59.70%59.69%61.03%61.70%
Upgrade
Operating Margin
26.10%23.65%24.93%24.26%25.15%22.68%
Upgrade
Profit Margin
27.53%24.60%20.50%21.62%18.34%21.89%
Upgrade
Free Cash Flow Margin
25.35%20.77%18.29%22.61%26.37%8.49%
Upgrade
EBITDA
1,8971,5881,5661,4091,3031,111
Upgrade
EBITDA Margin
29.17%26.95%28.43%27.83%28.74%26.32%
Upgrade
D&A For EBITDA
200.07194.26193.1180.69162.79153.86
Upgrade
EBIT
1,6971,3941,3721,2281,141957.38
Upgrade
EBIT Margin
26.10%23.65%24.93%24.26%25.15%22.68%
Upgrade
Effective Tax Rate
20.20%19.43%21.20%21.67%24.35%18.55%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.